Palvella Therapeutics, Inc (PVLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 4:15 PM ET
Palvella Therapeutics, Inc (PVLA) Statistics
Palvella Therapeutics (PVLA) has a market cap of $2.11B. Its share count is up 31.34% from a year earlier.
Total Valuation
| Market Cap | $2.11B |
|---|---|
| Latest price (Nov 17, 2026) | $144.35 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 72.42% over 52 weeks and trades 0.84% above its 50-day average.
| Beta (1Y) | 1.64 |
|---|---|
| 52-Week Change | +72.42% |
| 1-Month Change | +17.40% |
| 3-Month Change | -3.74% |
| 6-Month Change | +32.19% |
| Total Return (1Y) | +72.42% |
| Return vs SPY (1Y) | +62.48% |
| Max Drawdown (1Y) | -31.11% |
| Sharpe Ratio (1Y) | 0.68 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $143.15 |
| 200-Day Average | $131.10 |
| 52-Week Range | $72.22 to $179.95 |
| RSI (14 Days) | 47.0 |
| Average Volume (20 Days) | 283.38K |
Financial Position
Current assets cover 16.01x current liabilities.
| Current Ratio | 16.01x |
|---|---|
| Quick Ratio | 16.01x |
| Interest Coverage | -7.43x |
Returns and Efficiency
Return on equity is -37.89% and return on assets is -31.33% over the last 12 months.
| Return on Equity (ROE) | -37.89% |
|---|---|
| Return on Assets (ROA) | -31.33% |
| Return on Capital Employed (ROCE) | -29.44% |
| ROA (5Y Average) | -14.67% |
| ROIC (5Y Average) | 39.61% |
Scores
PVLA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$70.29M |
| Pretax Income | -$74.99M |
| Net Income | -$74.99M |
| EBIT | -$66.09M |
| Reported EPS (TTM) | -$5.50 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.67% of the $239.40M in total assets.
| Cash and Equivalents | $193.30M |
|---|---|
| Working Capital | $224.04M |
| Shareholder Equity | $197.92M |
| Book Value Per Share | $13.62 |
| Total Assets | $239.40M |
| Total Liabilities | $41.48M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $0 of capital spending, operating cash flow left -$43.06M of free cash flow.
| Operating Cash Flow | -$43.06M |
|---|---|
| Capital Expenditures | $0 |
| Free Cash Flow | -$43.06M |
| FCF Per Share | -$2.95 |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
PVLA does not pay a dividend. Its free cash flow yield is -2.05%.
| FCF Yield | -2.05% |
|---|---|
| Shareholder Yield | 0.00% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PVLA
What is PVLA's market cap?
Palvella Therapeutics has a market cap of $2.11B.
How many shares of PVLA are outstanding?
Palvella Therapeutics has 14.53M shares outstanding. The count is up 31.34% from a year earlier.
Does PVLA pay a dividend?
No. Palvella Therapeutics does not pay a dividend.
PVLA pages: Overview, Earnings, Forecast, Financials, Statistics, Competitors